Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 8551 - 8575 of 9261 in total
TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
Investigational
TRV120027 has been used in trials studying the treatment of Heart Failure and Kidney Disease.
Investigational
Experimental
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
Folate Fitc has been used in trials studying the diagnostic of Ovarian Cancer.
Investigational
Experimental
Experimental
Experimental
Experimental
Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have...
Investigational
Matched Description: … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein
Matched Salts cas: … 143851-98-3 …
Investigational
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Displaying drugs 8551 - 8575 of 9261 in total